Cubist

Merck Finally Gets Some Good News on Cubist
Merck Finally Gets Some Good News on Cubist
WSJ Online
Merck
Cubist
FDA
M&A
Zerbaxa
Flag link:
Cubist, Enanta and Vertex still await FDA approval decisions this year
Cubist, Enanta and Vertex still await FDA approval decisions this year
Bizjournals.com
Cubist
Enanta
Vertex Pharmaceuticals
FDA
Zerbaxa
ABT-450
Kalydeco
Flag link:
Merck Begins Tender Offer to Acquire Cubist
Merck Begins Tender Offer to Acquire Cubist
Yahoo
Merck
Cubist
M&A
Flag link:
Cubist nears another big antibiotic approval as M&A rumors simmer
Cubist nears another big antibiotic approval as M&A rumors simmer
Fierce Biotech
Cubist
antibiotics
M&A
ceftolozane/tazobactam
Flag link:
Cubist rises after saying greater Cubicin sales and acquisitions boosted its 4th-qtr revenue
Cubist rises after saying greater Cubicin sales and acquisitions boosted its 4th-qtr revenue
Yahoo/AP
Cubist
Cubicin
earnings
Flag link:
Three biopharma companies poised for product OKs in 2014: analyst
Three biopharma companies poised for product OKs in 2014: analyst
Marketwatch
Cubist
Regeneron
Spectrum
Flag link:
Cubist antibiotic succeeds in late-stage trial, shares rise
Cubist antibiotic succeeds in late-stage trial, shares rise
Reuters
ceftolozane/tazobactam
Cubist
antibiotics
intra-abdominal infections
Flag link:
Cubist Pharma's Buys Look Like Square Deals
Cubist Pharma's Buys Look Like Square Deals
Barron's
Cubist
M&A
Flag link:
Buying Into Cubist's Art Against Resistant Bacteria
Buying Into Cubist's Art Against Resistant Bacteria
Forbes
Cubist
antibiotic resistance
antibiotics
Cubicin
Andromeda
Flag link:
Cubist Increases Revenue 30% to $231 Million in the Second Quarter
Cubist Increases Revenue 30% to $231 Million in the Second Quarter
Yahoo
earnings
Cubist
Flag link:
Cubist Sues Hospira Over Cubicin Bacteria Medicine Patent
Cubist Sues Hospira Over Cubicin Bacteria Medicine Patent
Bloomberg
Cubicin
Cubist
Hospira
MRSA
Flag link:
Cubist Earnings Narrowly Exceed Expectations
Cubist Earnings Narrowly Exceed Expectations
Investors.com
earnings
Cubist
Flag link:
Cubist's antibiotic gets generic threat from Hospira
Cubist's antibiotic gets generic threat from Hospira
Reuters
Cubist
antibiotics
generics
Hospira
Cubicin
Flag link:
Cubist Pharmaceuticals extends offer to buy Adolor shares until Friday
Cubist Pharmaceuticals extends offer to buy Adolor shares until Friday
Yahoo/AP
Cubist
Adolor
tender offer
M&A
Flag link:
Biotech Takeovers Could Heat Up These Stocks
Biotech Takeovers Could Heat Up These Stocks
Seeking Alpha
M&A
Acorda
Alnylam
Adolor
Cubist
Chelsea Therapeutics
Catalyst
Human Genome Sciences
Flag link:
Cubist Pharmaceuticals-Adolor waiting period expires
Cubist Pharmaceuticals-Adolor waiting period expires
Bizjournals.com
Cubist
Adolor
M&A
Flag link:
Cubist’s merger partner Adolor swings to third-quarter profit
Cubist’s merger partner Adolor swings to third-quarter profit
Bizjournals.com
Cubist
M&A
earnings
Adolor
Flag link:
Cubist begins tender offer for Adolor
Cubist begins tender offer for Adolor
Bizjournals.com
Cubist
Adolor
M&A
Flag link:
Cubist's Adolor Acquisition Aligns Well With Its Own Skill Set
Cubist's Adolor Acquisition Aligns Well With Its Own Skill Set
Seeking Alpha
Adolor
Cubist
M&A
Flag link:
[video]Cubist CEO: We are not Pfizer
[video]Cubist CEO: We are not Pfizer
TheStreet.com
Pfizer
Adolor
Cubist
Pharma CEOs
M&A
Michael Bonney
Flag link:

Pages